UroStream

Editor’s Note: From November 10–16, 2025, the 9th West China Uro-Oncology Tianfu Academic Conference and the 11th Annual Meeting of the Genitourinary Tumor Committee of the Sichuan Anti-Cancer Association were…

With the rapid progress of clinical research, immunotherapy has demonstrated substantial value across multiple treatment settings in renal cell carcinoma (RCC). In particular, immune-based combination regimens have reshaped the treatment landscape of advanced RCC. At the 9th West China Uro-Oncology Tianfu Academic Conference & the 11th Annual Meeting of the Sichuan Anti-Cancer Association Genitourinary Tumor Committee, Professor Pei Dong from Sun Yat-sen University Cancer Center delivered a keynote lecture titled “Rational Reflections Amid the Surge of Immunotherapy in RCC.” After the session, Oncology Frontier – Urology Frontier invited Prof. Dong for an in-depth discussion on the evolving role of neoadjuvant therapy, adjuvant immunotherapy, and precision strategies for FH-deficient RCC. 

Editor’s Note: Prostate cancer is one of the most common malignant tumors of the male genitourinary system. Exploring innovative diagnostic and treatment strategies and promoting standardized whole-course management may further improve…

In recent years, the incidence of urological malignancies in China has risen steadily. Prostate, bladder, and kidney cancers now rank among the most common malignancies in the country, posing a serious threat to public health. The Department of Urology at the National Cancer Center / Cancer Hospital, Chinese Academy of Medical Sciences (CICAMS), has long been dedicated to the diagnosis and treatment of urological tumors. With extensive experience in laparoscopic and minimally invasive surgery as well as multidisciplinary cancer management, it stands as a leading force in China’s field of urologic oncology.

Bladder cancer is one of the most common malignant tumors of the genitourinary system. In recent years, the emergence of antibody-drug conjugates (ADCs) has brought new hope for patients with advanced bladder cancer. Among them, Enfortumab Vedotin (EV) — an ADC targeting the tumor antigen Nectin-4 — has been hailed as a “precision-guided missile.” However, the molecular mechanisms underlying the variability in EV’s therapeutic response have not been fully elucidated.

Bladder cancer is one of the most common malignancies of the urinary system. Radical cystectomy remains one of the standard treatments, and urinary diversion is a crucial component of this complex procedure.Professor Xing Nianzeng and his team pioneered a novel laparoscopic-friendly orthotopic ileal neobladder reconstruction technique, known as the “Xing’s Neobladder.” This innovative approach utilizes a detubularized ileal segment to construct a spherical, orthotopic ileal neobladder with two peristaltic input loops, preventing urinary reflux and avoiding excessive tension or compression on the left ureter. The design helps preserve upper urinary tract function while ensuring physiological urine flow.During the National Cancer Center Urological Oncology Conference & Medical Frontier Forum (NCCU 2025), Oncology Frontier – Urology Frontier invited Professor  Yong Zhang from the National Cancer Center / National Clinical Research Center for Cancer / Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, to share his insights on this groundbreaking technique.

From September 10 to 14, 2025, the 28th Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) was held in Jinan, Shandong. With the theme “Standardizing Diagnosis and Treatment, Leading Innovation”, the conference brought together leading domestic and international scholars. The Renal Cancer session featured the highly anticipated release of the 2025 CSCO Renal Cancer Guidelines, setting a new standard for improving treatment outcomes and promoting standardized care across China. Following the conference, Oncology Frontier – Urology Frontier invited Professor Fangjian Zhou from Sun Yat-sen University Cancer Center to discuss the groundbreaking advances in renal cancer management and the quality-control experience of the Guangdong Cancer Center.

On August 22–23, 2025, the 2025 Pujiang Uro-Oncology Conference was held in Shanghai, bringing together leading experts to discuss advances in urologic oncology. This article is based on the pre-conference session presented by Professor Youyan Guan (Cancer Hospital, Chinese Academy of Medical Sciences) and Professor Xiongjun Ye, titled “Comprehensive Management of Renal Cancer Patients.” Their lecture systematically reviewed the evolution of treatment concepts, perioperative and advanced-stage strategies, and the construction of comprehensive management systems, aiming to provide clinical and research colleagues with valuable reference and guidance.

Editor’s Note: On August 22–23, 2025, the highly anticipated 2025 Pujiang Uro-Oncology Conference was held in Shanghai, gathering leading experts in urologic oncology from across China and abroad. Among the key topics was the optimization of treatment strategies for metastatic hormone-sensitive prostate cancer (mHSPC). Professor Xinan Sheng from Peking University Cancer Hospital delivered an insightful lecture titled “The Combination Revolution in mHSPC — Multi-Strategy Optimization of Patient Management.” His talk provided a systematic review of the current treatment landscape, key challenges, and future directions for mHSPC management.